866-997-4948(US-Canada Toll Free)

Gallbladder Cancer - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 118 Pages

Gallbladder Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H1 2017, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gallbladder Cancer - Overview
Gallbladder Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gallbladder Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gallbladder Cancer - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Array BioPharma Inc
Aslan Pharmaceuticals Pte Ltd
Bayer AG
BeiGene Ltd
Eli Lilly and Company
Halozyme Therapeutics Inc
Hutchison China MediTech Ltd
Leap Therapeutics Inc
Merrimack Pharmaceuticals Inc
Novartis AG
NuCana BioMed Ltd
Threshold Pharmaceuticals Inc
VasGene Therapeutics Inc
Gallbladder Cancer - Drug Profiles
apatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGBA-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
binimetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
copanlisib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DKN-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
evofosfamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMPL-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
irinotecan hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUC-1031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEGPH-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ramucirumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trametinib dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varlitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vas-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gallbladder Cancer - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Gallbladder Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
Gallbladder Cancer - Pipeline by Array BioPharma Inc, H1 2017
Gallbladder Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017
Gallbladder Cancer - Pipeline by Bayer AG, H1 2017
Gallbladder Cancer - Pipeline by BeiGene Ltd, H1 2017
Gallbladder Cancer - Pipeline by Eli Lilly and Company, H1 2017
Gallbladder Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
Gallbladder Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017
Gallbladder Cancer - Pipeline by Leap Therapeutics Inc, H1 2017
Gallbladder Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
Gallbladder Cancer - Pipeline by Novartis AG, H1 2017
Gallbladder Cancer - Pipeline by NuCana BioMed Ltd, H1 2017
Gallbladder Cancer - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H1 2017
Gallbladder Cancer - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Gallbladder Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *